Broadening the field of opportunity for medicinal chemists. Official journal of the European Federation for Medicinal Chemistry
Impact Factor 2.626 12 Issues per Year
Concise Article

Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

Show Affiliations
Hide Affiliations
*
Corresponding authors
a
Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca, Alderley Park, Macclesfield, UK
E-mail: william.mccoull@astrazeneca.com ;
Tel: +44 (0)1625 519444
b
Medicines Evaluation Pharmaceutical Development, AstraZeneca R&D, 151 85 Södertälje, Sweden
c
Proteros biostructures GmbH, Am Klopferspitz 19, Martinsried, Germany
Med. Chem. Commun., 2014,5, 57-63

DOI: 10.1039/C3MD00234A
Received 21 Aug 2013, Accepted 04 Nov 2013
First published online 06 Nov 2013
| | | | | | More
Please wait while Download options loads
Download Citation
 
 

Supplementary Info